Binds IL-5 with high affinity and prevents IL-5 from interacting with its receptor on eosinophils, reducing eosinophil maturation, survival and inflammatory activity. Its extended duration supports dosing every six months.
Indications / reported uses
Add-on maintenance treatment of severe asthma characterised by an eosinophilic phenotype in adults and paediatric patients aged 12 years and older under the US FDA indication; not for acute bronchospasm or status asthmaticus
Add-on therapy with intranasal corticosteroids for severe chronic rhinosinusitis with nasal polyps (CRSwNP) in adults under the EMA/Australian product indications where systemic corticosteroids and/or surgery have not provided adequate control
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Depemokimab Environmental Risk Assessment (ERA) (the Depemokimab ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.